To address how trials are designed to minimize bias and non-specific effects, this session will review historic trends and research in placebo response. Data and evidence for intervention methods will be discussed, including the use of advanced analytic approaches, participant and investigator training, and measurement strategies. We will also discuss how in addition to clinical outcomes such as disease progression, patient-reported outcomes (PROs) are commonly included in oncology clinical trials because they provide important insight into how patients feel or function. To investigate potential bias in results, we performed statistical simulations and analyzed all collected data versus only data collected at the start of the cycle using different repeated measurement models.
